Capricor Therapeutics filings document a Delaware biotechnology issuer developing cell and exosome-based therapeutics, including Deramiocel for Duchenne muscular dystrophy. Its 8-K reports record quarterly and annual financial results, FDA communications tied to the Deramiocel Biologics License Application, Regulation FD disclosures, and material-event reporting for litigation-related actions.
Proxy materials address board elections, executive compensation, equity awards, shareholder voting matters, and other governance disclosures. The filing record also identifies CAPR common stock, par value $0.001 per share, as a Nasdaq-listed security and provides formal disclosure around operating results, capital structure, and public-company status.
Capricor Therapeutics director Frank Litvack reported a routine option exercise. He exercised stock options covering 3,937 shares of Common Stock at $1.39 per share, converting a derivative position into direct share ownership. Following the exercise, he holds 133,776 Common shares directly and 46,278 Common shares indirectly through the Litvack Curtis Family Trust, where he serves as trustee. The exercised option grant, originally issued in 2016, had been adjusted for a 1-for-10 reverse stock split in 2019 and a share reprice in 2020. No open-market purchases or sales were reported in this filing.
Capricor Therapeutics reported first quarter 2026 results with a net loss of $33.9 million, compared with $24.4 million a year earlier, as it continues late-stage development of Deramiocel for Duchenne muscular dystrophy. Revenue was $0 for both periods, reflecting the company’s pre-commercial stage.
Research and development expenses increased to $27.4 million from $18.9 million, while general and administrative costs rose to $9.4 million from $6.1 million. Investment income grew to $2.9 million, partially offsetting operating losses. Cash, cash equivalents and marketable securities totaled $278.6 million as of March 31, 2026, down from $318.1 million at December 31, 2025.
Management highlighted ongoing FDA review of its Biologics License Application for Deramiocel, with a PDUFA target action date of August 22, 2026, and noted recent legal action involving NS Pharma related to commercialization arrangements and patient access.
CAPRICOR THERAPEUTICS, INC. EVP and general counsel Karen Krasney reported an exercise-and-sell transaction in the company’s common stock. She sold 25,000 shares in an open-market sale on May 1, 2026 at a weighted average price of $31.7019 per share, under a pre-arranged Rule 10b5-1 trading plan.
On the same date, she exercised stock options to acquire 25,000 shares of common stock at an exercise price of $3.18 per share. Following these transactions, she directly holds 30,547 shares of Capricor common stock.
Capricor Therapeutics chief financial officer Anthony Bergmann executed a combined option exercise and share sale involving 25,000 shares of common stock. He exercised stock options to acquire 25,000 shares at $3.18 per share, then sold 25,000 shares in an open‑market transaction at a weighted average price of $31.7016 per share.
The sale was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted in December 2025, meaning the trades were scheduled in advance. After these transactions, Bergmann holds 8,223 shares of common stock directly and 116,980 stock options with a $3.18 exercise price expiring in 2032.
Capricor Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders on June 4, 2026, to elect eight directors, ratify its independent auditor, hold advisory votes on executive pay and pay frequency, and approve a charter amendment for officer exculpation.
The meeting will be held in person at the company’s San Diego headquarters, with April 6, 2026 set as the record date for the 57,840,102 shares of common stock entitled to vote. The proxy statement details board composition and independence, committee structures, executive and director compensation, and stockholder proposal mechanics for future annual meetings.
It also describes significant commercial distribution agreements for Deramiocel with Nippon Shinyaku in the United States and Japan, including upfront and milestone payments and revenue-sharing terms, as well as the company’s equity incentive plans and insider trading, hedging and pledging policies.
CAPRICOR THERAPEUTICS, INC. director Karimah Es Sabar exercised stock options to acquire 7,529 shares of Common Stock at $3.18 per share and, on the same date, sold all 7,529 shares at $32.00 per share.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating the transactions were scheduled in advance rather than timed opportunistically. Following these transactions, the reporting person held no Common Stock directly.
CAPR proposed sale notice: The filing lists 7,529 shares of Common Stock to be sold on 04/02/2026 in connection with an exercise of stock options for cash. It also reports recent 10b5-1 sales by Karimah Es Sabar of 53,735 and 61,265 shares on 04/01/2026 and 03/31/2026, respectively, with proceeds shown.